Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Immunogenicity of biologics used in the treatment of inflammatory bowel disease

Immunogenicity of biologics used in the treatment of inflammatory bowel disease PURPOSE OF THE REVIEW:Here we critically evaluate the literature on immunotherapy failure in inflammatory bowel disease patients. In particular anti-drug antibody production, and subsequently loss of response as the primary cause of immunotherapy failure in IBD patients. The benefits of shifting from the “standard” empirical dose escalation approach to therapeutic drug monitoring with anti-TNFα therapy is explored.RECENT FINDINGS:The American Gastroenterology Association and British Society of Gastroenterology both currently recommend the use of reactive therapeutic drug monitoring to guide treatment, following loss of response in inflammatory bowel disease patients with active disease. However, further research is required to prove the efficacy of a proactive therapeutic drug monitoring approach alone in remitted IBD patients.SUMMARY:A combination of personalised monitoring approach for anti-drug antibodies and therapeutic drug monitoring could provide beneficial treatment outcome for people with inflammatory bowel disease by predicting drug failure prior to clinical symptoms and allowing timely switching to an alternative drug. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Human Antibodies IOS Press

Immunogenicity of biologics used in the treatment of inflammatory bowel disease

Human Antibodies , Volume 29 (4): 11 – Nov 22, 2021

Loading next page...
 
/lp/ios-press/immunogenicity-of-biologics-used-in-the-treatment-of-inflammatory-g50Jsn0Hba
Publisher
IOS Press
Copyright
Copyright © 2021 © 2021 – IOS Press. All rights reserved.
ISSN
1093-2607
eISSN
1875-869X
DOI
10.3233/HAB-210449
Publisher site
See Article on Publisher Site

Abstract

PURPOSE OF THE REVIEW:Here we critically evaluate the literature on immunotherapy failure in inflammatory bowel disease patients. In particular anti-drug antibody production, and subsequently loss of response as the primary cause of immunotherapy failure in IBD patients. The benefits of shifting from the “standard” empirical dose escalation approach to therapeutic drug monitoring with anti-TNFα therapy is explored.RECENT FINDINGS:The American Gastroenterology Association and British Society of Gastroenterology both currently recommend the use of reactive therapeutic drug monitoring to guide treatment, following loss of response in inflammatory bowel disease patients with active disease. However, further research is required to prove the efficacy of a proactive therapeutic drug monitoring approach alone in remitted IBD patients.SUMMARY:A combination of personalised monitoring approach for anti-drug antibodies and therapeutic drug monitoring could provide beneficial treatment outcome for people with inflammatory bowel disease by predicting drug failure prior to clinical symptoms and allowing timely switching to an alternative drug.

Journal

Human AntibodiesIOS Press

Published: Nov 22, 2021

There are no references for this article.